

Supporting Information

for

A speedy route to sterically encumbered, benzene-fused derivatives of privileged, naturally occurring hexahydropyrrolo[1,2-*b*]isoquinoline

Olga Bakulina, Alexander Ivanov, Vitalii Suslonov, Dmitry Dar'in and Mikhail Krasavin*.[§]

Address: Institute of Chemistry, Saint Petersburg State University, 26 Universitetsky prospekt, Peterhof 198504, Russia;

Email: Mikhail Krasavin - m.krasavin@spbu.ru

*Corresponding Author

[§]ORCID Mikhail Krasavin: 0000-0002-0200-4772

Detailed experimental procedures, analytical data and copies of ¹H and ¹³C NMR spectra for all new compounds; crystallographic data for compounds **10 and **13e**; results of correlational and variable temperature NMR experiments**

Table of Contents

1. Experimental section.....	S2
2. NMR studies for compounds 10d and 10e	S11
3. Relative configuration determination for compounds 10k and 10m	S17
4. Relative configuration determination for compound 10o	S17
5. Crystallographic data for compounds 10 and 13e	S19
6. References.....	S24
7. Copies of ¹ H and ¹³ C NMR spectra of compounds 9 and 10	S25

1. EXPERIMENTAL SECTION

General information. NMR spectroscopic data were recorded with a 400 MHz (400.13 MHz for ^1H and 100.61 MHz for ^{13}C) and a 500 MHz (500.03 MHz for ^1H and 125.7 MHz for ^{13}C) spectrometers in $\text{DMSO}-d_6$ or in CDCl_3 and were referenced to residual solvent proton signals ($\delta_{\text{H}} = 7.26$ and 2.50 ppm, respectively) and solvent carbon signals ($\delta_{\text{C}} = 77.2$ and 39.5 ppm, respectively). Coupling constants, J are reported in Hz. Melting points were determined with an automated heat block instrument and are uncorrected. Mass spectra were recorded with a HRMS-ESI-qTOF spectrometer (electrospray ionization mode). X-ray single crystal analyses were performed with monochromated Mo K α or Cu K α radiation, respectively. Column chromatography was performed on silica gel 60 (230–400 mesh). For TLC analysis UV₂₅₄ silica gel coated plates were used. MeCN was distilled from P_2O_5 and stored over molecular sieves 4 Å. Homophthalic anhydride was acquired from a commercial source, stored at 5 °C and used as received. All indolenines **9** were stored in sealed vials at 5 °C in the dark.

CCDC 1503093 (**13e**), 1503094 (*anti*-**10c**), 1503095 (*anti*-**10d**), 1503096 (*anti*-**10g'**), 1503097 (*anti*-**10e**), 1503098 (*anti*-**10a'**), 1503099 (*anti*-**10f**), 1503100 (*syn*-**10a'**), 1503101 (*syn*-**10f**), 1503102 (*anti*-**10e'**), 1503103 (*anti*-**10n**), 1503104 (*anti*-**10i**), 1503105 (*syn*-**10e**), 1503106 (*anti*-**10l**), 1470399 (*anti*-**10b**), 1470389 (*anti*-**10h**), 1461790 (*anti*-**10j**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <http://www.ccdc.cam.ac.uk>.

Indolenines 9. Indolenines **9a-b** [1], **9d-g** [1], **9h** [2], **9i** [3], **9j** [4], **9k** [5], **9p** [6] are known compounds and were prepared from the arylhydrazine hydrochlorides and respective aldehydes or ketones according to the literature protocols.

General procedure 1. Synthesis of indolenines 9c,l,n,o,q-t. To a screw-cap vial containing a suspension of the corresponding aryl hydrazine hydrochloride in glacial AcOH (15 mL) carbonyl compound (1.1 equiv) was added in one portion. The reaction mixture was stirred at 55–60 °C for 4 h (or at reflux for 2–16 h) and concentrated in vacuo at 40 °C. The residue was diluted with DCM (50 mL) and filtered through Celite. The resulting solution was passed through a short pad of silica, washed with sat. NaHCO_3 and water. The organic layer was dried over Na_2SO_4 and concentrated under reduced pressure to give pure indolenines **9c,l,s**. Indolenines **9n,o,q-r,t** were subjected to extra column chromatography.

5'-Fluorospiro[cyclohexane-1,3'-indole] (9c). The title compound was prepared from 4-fluorophenylhydrazine hydrochloride (1.51 g, 9.3 mmol) and cyclohexanecarboxaldehyde (1.14 g, 10.2 mmol) according to general procedure 1. Light yellow solid. Yield 1.39 g (74%). ^1H NMR (400 MHz, CDCl_3) δ 8.34 (s, 1H), 7.59 (dd, $J=8.4, 4.7$, 1H), 7.18 – 6.92 (m, 2H), 2.00 – 1.55 (m, 10H). ^{13}C NMR (101 MHz, CDCl_3) δ = 178.1 (d, $J=3.6$), 161.6 (d, $J=244.7$), 150.3, 146.7 (d, $J=8.8$), 121.8 (d, $J=9.0$), 114.3 (d, $J=23.8$), 110.0 (d, $J=24.7$), 58.3 (d, $J=2.2$), 31.6, 25.4, 23.8. HRMS (ESI) m/z [$\text{M}+\text{H}$] $^+$: Calcd for $\text{C}_{13}\text{H}_{14}\text{FN}$: 204.1183. Found: 204.1171.

4 α -Methyl-2,3,4,4a-tetrahydro-1H-carbazole (9l) [7]. The title compound was prepared from phenylhydrazine hydrochloride (0.72 g, 5 mmol) and 2-methylcyclohexanone (0.62 g, 5.5 mmol) according to general procedure 1 (reflux, 2 h). Yield 600 mg (65%). Beige solid. ^1H NMR (400 MHz, CDCl_3) δ 7.62 (d, $J=7.7$, 1H), 7.39 – 7.26 (m, 2H), 7.21 (t, $J=7.4$, 1H), 2.95 – 2.78 (m, 1H),

2.61 (td, $J=13.3$, 5.7, 1H), 2.38 – 2.13 (m, 2H), 1.91 – 1.60 (m, 2H), 1.43 (qd, $J=13.2$, 8.9, 1H), 1.33 (s, 3H), 1.18 (td, $J=13.3$, 4.2, 1H).

2-Methyl-2',3',5',6'-tetrahydrospiro[indole-3,4'-pyran] (9m). A mixture of 4-acetylpyrane (2.05 g, 16.0 mmol), phenylhydrazine (1.73 g, 16.0 mmol) and *p*-toluenesulfonic acid monohydrate (100 mg, 5.3 mmol) was refluxed in benzene (40 mL) with a Dean-Stark trap for 3 h. The volatiles were removed in vacuo followed by column chromatography (hexane-EtOAc from 4:1 to 5:2) affording 2.0 g of 1-phenyl-2-(1-(tetrahydro-2*H*-pyran-4-yl)ethylidene)hydrazine with impurity. The obtained compound was refluxed in 30 mL of AcOH for 3 h. The reaction mixture was concentrated, redissolved in CHCl₃ and washed with water. The organic layer was dried over Na₂SO₄ and concentrated to give crude **9m**, which was purified by column chromatography (hexane-EtOAc from 1:1 to 2:3). Yield 550 mg (19%). Beige solid. ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, $J=7.4$, 1H), 7.59 (d, $J=7.6$, 1H), 7.38 (t, $J=7.5$, 1H), 7.21 (t, $J=7.5$, 1H), 4.20 – 3.90 (m, 4H), 2.34 (s, 3H), 2.26 – 2.12 (m, 2H), 1.28 – 1.25 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 185.9, 154.2, 143.8, 128.2, 124.8, 123.8, 120.6, 63.6, 55.1, 30.8, 16.2. HRMS (ESI) m/z [M+H]⁺: Calcd for C₁₃H₅NO: 202.1226. Found: 202.1246.

2'-Methylspiro[cyclohexane-1,3'-indole] (9n) [8]. The title compound was prepared from phenylhydrazine hydrochloride (1.66 g, 11.5 mmol) and cyclohexylmethylketone (1.59 g, 12.6 mmol) according to general procedure 1 (reflux, 16 h). Column chromatography (CHCl₃) afforded 685 mg (34%) of **9n** as beige solid. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, $J=7.5$, 1H), 7.58 (d, $J=7.7$, 1H), 7.36 (td, $J=7.6$, 1.1, 1H), 7.19 (td, $J=7.5$, 1.0, 1H), 2.31 (s, 3H), 2.06 – 1.88 (m, 3H), 1.88 – 1.73 (m, 4H), 1.60 – 1.40 (m, 1H), 1.41 – 1.23 (m, 2H).

3,3-Dimethyl-2-(*p*-tolyl)-3*H*-indole (9o) [9]. The title compound was prepared from phenylhydrazine hydrochloride (0.94 g, 6.5 mmol) and 2-methyl-1-(*p*-tolyl)propan-1-one (1.2 g, 7.2 mmol) according to general procedure 1 (reflux, 16 h). Column chromatography (eluting with CHCl₃-hexane 1:4) afforded 890 mg (58%) of **9o** as viscous yellowish oil. ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, $J=8.2$, 2H), 7.69 (d, $J=7.6$, 1H), 7.41 – 7.16 (m, 5H), 2.43 (s, 3H), 1.59 (s, 6H).

3,3-Dimethyl-2-propyl-3*H*-indole (9q) and 2,3-dimethyl-3-propyl-3*H*-indole [10] (9r). The mixture of title compounds was prepared from phenylhydrazine hydrochloride (3.74 g, 26 mmol) and 2-methylhexan-3-one (3.26 g, 28.6 mmol) according to general procedure 1. Column chromatography (eluting with CHCl₃-hexane from 1:2 to 1:1) afforded pure indolenines **9r** and **9s**.

(9q): Yield 892 mg (18%), orange oil. ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, $J=7.7$, 1H), 7.37 – 7.27 (m, 2H), 7.25 – 7.16 (m, 1H), 2.60 – 2.50 (m, 2H), 2.01 – 1.83 (m, 2H), 1.33 (s, 6H), 1.08 (t, $J=7.4$, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 191.1, 154.0, 145.8, 127.7, 125.2, 121.3, 120.2, 53.9, 31.1, 23.3, 20.0, 14.4. HRMS (ESI) m/z [M+H]⁺: Calcd for C₁₃H₁₇N: 188.1434. Found: 188.1438.

(9r): Yield 550 mg (11%), orange oil. ¹H NMR (400 MHz, CDCl₃) δ = 7.53 (d, $J=7.6$, 1H), 7.34 – 7.10 (m, 3H), 2.25 (s, 3H), 1.91 – 1.79 (m, 1H), 1.77 – 1.67 (m, 1H), 1.28 (s, 3H), 0.87 – 0.55 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) 187.1, 154.2, 143.3, 127.4, 125.1, 121.6, 119.9, 57.7, 39.7, 22.6, 17.5, 15.5, 14.0. HRMS (ESI) m/z [M+H]⁺: Calcd for C₁₃H₁₇N: 188.1434. Found: 188.1429.

2'-Cyclohexylspiro[cyclohexane-1,3'-indole] (9s). Phenylhydrazine hydrochloride (0.86 g, 6.5 mmol) and dicyclohexylketone (1.38 g, 7.1 mmol) were reacted according to general procedure 1 (reflux, 6h). Crystallization from hexane-DCM-EtOAc mixture (2:1:2) gave **9s**-hydrochloride as

light yellow solid. Yield 0.5 g (29%). The prepared compound (500 mg, 1.6 mmol) was dissolved in CHCl_3 (50 mL), washed with NaHCO_3 saturated solution (25 mL) and water. The organic layer was dried over Na_2SO_4 and concentrated *in vacuo* to give pure **9s**. Yield 401 mg (91%). ^1H NMR (400 MHz, CDCl_3) δ 7.70 (d, $J=7.4$, 1H), 7.61 (d, $J=7.7$, 1H), 7.32 (td, $J=7.6$, 1.1, 1H), 7.15 (td, $J=7.5$, 1.0, 1H), 2.65 – 2.53 (m, 1H), 2.05 – 1.60 (m, 14H), 1.54 – 1.42 (m, 1H), 1.42 – 1.32 (m, 3H), 1.27 – 1.17 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 194.7, 144.1, 127.6, 124.4, 124.3, 120.4, 58.7, 38.5, 32.4, 30.1, 26.7, 26.0, 25.5, 21.8. HRMS (ESI) m/z $[\text{M}+\text{H}]^+$: Calcd for $\text{C}_{19}\text{H}_{25}\text{N}$: 268.2060. Found: 268.2051.

2'-(*p*-Tolyl)spiro[cyclohexane-1,3'-indole] (9t). The title compound was prepared from phenylhydrazine hydrochloride (0.53 g, 3.7 mmol) and cyclohexyl(*p*-tolyl)methanone (0.83 g, 4.1 mmol) according to general procedure 1 (reflux, 16 h). Column chromatography (eluting with CHCl_3 -hexane 1:4) afforded 650 mg (64%) of **9t** as viscous yellow oil. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.07 (d, $J=8.3$, 1H), 7.87 (d, $J=7.4$, 1H), 7.63 (d, $J=7.3$, 1H), 7.39 (td, $J=7.6$, 1.0, 1H), 7.33 (d, $J=8.1$, 1H), 7.23 (td, $J=7.5$, 1.0, 1H), 2.38 (s, 3H), 2.34 – 2.21 (m, 2H), 2.02 – 1.88 (m, 3H), 1.81 – 1.72 (m, 2H), 1.65 – 1.50 (m, 1H), 1.27 – 1.21 (m, 2H). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 182.1, 153.3, 146.3, 140.1, 130.1, 129.1, 128.4, 127.5, 124.7, 124.3, 120.7, 57.5, 30.8, 24.5, 21.2, 20.9. HRMS (ESI) m/z $[\text{M}+\text{H}]^+$: Calcd for $\text{C}_{20}\text{H}_{21}\text{N}$: 276.1747. Found: 276.1758.

General procedure 2. Synthesis of compounds 10. A mixture of homophthalic anhydride (1 equiv.) and the corresponding indolenine **9a–t** (1 equiv) was placed in a sealed screw-cap vial, dissolved in dry acetonitrile (2 mL per 1 mmol) and stirred at room temperature for time indicated in Table 1. The reaction mixture was cooled to -14°C , the resulting precipitate was filtered and washed with minimum amount of cold acetonitrile to give pure compound **10**.

General procedure 3. Synthesis of methyl esters 10'. The Castagnoli-Cushman product **10** was dissolved in dry acetone (10 mL per 1 mmol). Methyl iodide (2.5 equiv) and K_2CO_3 (2.5 equiv) were added to the solution and the resulting suspension was stirred for 24 h at room temperature. The volatiles were removed *in vacuo*. The residue was dissolved in DCM, washed with water, brine, dried over Na_2SO_4 and concentrated to give crude methyl ester **10'**, which was purified by column chromatography on silica gel.

(*RS,RS*)-6'-Oxo-11',11a'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylic acid (*anti*-10a). The title compound was prepared according to general procedure 2 (1.9 mmol scale). The product was obtained as white solid, mp $251\text{--}252^\circ\text{C}$ (decomp.). Yield 368 mg, 56%. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.68 (s, 1H), 8.42 (d, $J = 7.9$ Hz, 1H), 8.19 – 8.00 (m, 1H), 7.74 (d, $J = 7.6$ Hz, 1H), 7.64 (td, $J = 7.6$, 1.1 Hz, 1H), 7.50 (t, $J = 7.5$ Hz, 1H), 7.31 – 7.25 (m, 2H), 7.10 (t, $J = 7.3$ Hz, 1H), 4.36 (d, $J = 12.9$ Hz, 1H), 4.32 (d, $J = 12.8$ Hz, 1H), 2.17 – 1.97 (m, 1H), 1.95 – 1.75 (m, 4H), 1.75 – 1.63 (m, 1H), 1.64 – 1.49 (m, 3H), 1.27 – 1.11 (m, 1H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 172.9, 161.0, 140.7, 138.8, 136.2, 132.8, 128.6, 127.8, 127.7, 127.5, 125.7, 125.6, 123.5, 116.0, 68.7, 46.3, 46.0, 34.0, 31.2, 25.1, 22.1, 20.0.; HRMS (ESI) m/z $[\text{M}+\text{H}]^+$: Calcd for $\text{C}_{22}\text{H}_{21}\text{NO}_3$: 348.1594. Found: 348.1586.

The filtrate was concentrated and subjected to esterification according general procedure 3 and column chromatography (hexane- Me_2CO 7:1) to give some extra products *anti*-10a' and *syn*-10a'.

(RS,RS)-Methyl 11a,12,12-trimethyl-6-oxo-6,11,11a,12-tetrahydroindolo[1,2-*b*]isoquinoline-11-carboxylate (*anti*-10a'). Yield 84 mg, 12%. White solid, mp 158–159 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, *J*=8.1, 1H), 8.25 (d, *J*=7.3, 1H), 7.70 (d, *J*=7.6, 1H), 7.62 – 7.39 (m, 2H), 7.32 (t, *J*=7.7, 1H), 7.16 – 6.94 (m, 2H), 4.44 (d, *J*=13.0, 1H), 4.39 (d, *J*=12.9, 1H), 3.95 (s, 3H), 2.19 – 2.01 (m, 1H), 2.01 – 1.86 (m, 2H), 1.86 – 1.71 (m, 2H), 1.70 – 1.44 (m, 4H), 1.35 – 1.18 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 172.4, 161.9, 141.2, 138.8, 135.5, 132.7, 129.2, 128.7, 128.3, 128.1, 125.8, 125.5, 123.8, 117.18, 69.4, 52.5, 46.7, 46.7, 34.5, 31.9, 25.7, 23.0, 20.6; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₃H₂₃NO₃: 362.1751. Found: 362.1758.

(RS,SR)-Methyl 11a,12,12-trimethyl-6-oxo-6,11,11a,12-tetrahydroindolo[1,2-*b*]isoquinoline-11-carboxylate (*syn*-10a'). Yield 50 mg, 7%. White solid, mp 152–153 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.39 (d, *J*=7.9, 1H), 8.19 (dd, *J*=6.0, 3.0, 1H), 7.55 – 7.43 (m, 2H), 7.44 – 7.35 (m, 1H), 7.33 – 7.20 (m, 2H), 7.06 (t, *J*=7.5, 1H), 4.49 (d, *J*=3.2, 1H), 4.13 (d, *J*=3.2, 1H), 3.40 (s, 3H), 1.97 – 1.44 (m, 10H); ¹³C NMR (101 MHz, CDCl₃) δ 171.2, 162.6, 142.0, 139.5, 136.2, 132.5, 131.0, 129.3, 129.2, 128.3, 127.6, 123.8, 123.3, 116.0, 70.1, 52.6, 46.9, 46.8, 42.3, 32.2, 25.5, 23.6, 22.7; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₃H₂₃NO₃: 362.1751. Found: 362.1765.

(RS,RS)-2'-Methyl-6'-oxo-11',11a'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylic acid (*anti*-10b). The title compound was prepared according to general procedure 2 (1 mmol scale). The product was obtained as white solid, mp 286–287 °C (decomp.). Yield 268 mg, 73%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.85 (s, 1H), 8.45 (d, *J*=8.2, 1H), 8.22 (dd, *J*=7.7, 1.0, 1H), 7.79 (td, *J*=7.6, 1.3, 1H), 7.71 (s, 1H), 7.66 (t, *J*=7.5, 1H), 7.41 (d, *J*=7.7, 1H), 7.26 (d, *J*=8.1, 1H), 4.51 (d, *J*=12.9, 1H), 4.45 (d, *J*=12.9, 1H), 2.50 (s, 3H), 2.32 – 2.17 (m, 1H), 2.08 – 1.62 (m, 8H), 1.43 – 1.26 (m, 1H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 173.0, 160.6, 139.0, 138.4, 136.1, 132.7, 132.6, 128.6, 127.8, 127.6, 126.3, 125.6, 115.7, 68.8, 46.3, 46.0, 34.0, 31.1, 25.16, 22.2, 21.0, 20.0; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₃H₂₃NO₃: 362.1751. Found: 362.1751.

The filtrate was subjected to esterification according general procedure 3 and column chromatography (eluent – CHCl₃) to give some extra product methyl ester *syn*-10b';

(RS,SR)-Methyl 2'-methyl-6'-oxo-11',11a'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylate (*syn*-10b'). Viscous yellow oil. Yield 48 mg, 13%. ¹H NMR (400 MHz, CDCl₃) δ 8.32 – 8.21 (m, 1H), 8.21 – 8.08 (m, 1H), 7.54 – 7.42 (m, 2H), 7.44 – 7.35 (m, 1H), 7.15 – 7.01 (m, 2H), 4.48 (d, *J*=3.3, 1H), 4.12 (d, *J*=3.3, 1H), 3.41 (s, 3H), 2.35 (s, 3H), 1.92 – 1.46 (m, 10H); ¹³C NMR (101 MHz, CDCl₃) δ 171.1, 162.0, 139.5, 139.5, 136.0, 133.2, 132.2, 130.9, 129.0, 129.0, 128.7, 127.4, 123.9, 115.6, 70.0, 52.5, 46.7, 46.6, 42.2, 32.1, 25.4, 23.5, 22.6, 21.5; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₄H₂₅NO₃: 376.1907. Found: 376.1922.

2'-Fluoro-6'-oxo-11',11a'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylic acid (*anti*/*syn*-10c). The title compound was prepared according to general procedure 2 (1.2 mmol scale). The product was obtained as white solid, mp 263–265 °C (decomp.). Yield 295 mg, 66% (*anti*/*syn* = 3.3:1). Crystallization from MeCN gave *anti*-10c as a single isomer (151 mg, 34%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.71 (s, 1H), 8.41 (dd, *J*=8.7, 5.3, 1H), 8.06 (d, *J*=7.5, 1H), 7.64 (t, *J*=7.2, 1H), 7.58 – 7.41 (m, 2H), 7.25 (d, *J*=7.6, 1H), 7.16 – 6.98 (m, 1H), 4.37 (s, 2H), 2.10 – 1.94 (m, 1H), 1.92 – 1.47 (m, 8H), 1.26 – 1.06 (m, 1H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ = 173.1, 161.0, 158.4 (d, *J*_{CF} = 239.6), 141.1 (d, *J*_{CF} = 7.7), 137.4 (d, *J*_{CF} = 1.4), 136.3, 133.0, 128.6,

128.1, 127.8, 125.8, 117.0 (d, $J_{\text{CF}}=8.3$), 113.9 (d, $J_{\text{CF}}=22.6$), 113.3 (d, $J_{\text{CF}}=24.8$), 69.2, 46.5, 46.3 (d, $J_{\text{CF}}=1.0$), 33.9, 31.2, 25.2, 22.1, 20.2; HRMS (ESI) m/z $[M+H]^+$: Calcd for $\text{C}_{22}\text{H}_{20}\text{FNO}_3$: 366.1500. Found: 366.1509.

(*RS,RS*)-4'-Methyl-6'-oxo-11',11*a*'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylic acid (*anti*-10d). The title compound was prepared according to general procedure 2 (3 mmol scale). The product was obtained as white solid, mp 210–212 °C (decomp.). Yield 907 mg, 84%. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.04 (dd, $J=7.8, 1.0$, 1H), 7.61 (td, $J=7.6, 1.3$, 1H), 7.55 – 7.36 (m, 3H), 7.17 – 7.04 (m, 2H), 4.38 (d, $J=3.3$, 1H), 4.25 (d, $J=3.3$, 1H), 2.05 – 1.91 (m, 1H), 1.83 – 1.56 (m, 4H), 1.45 – 1.12 (m, 4H), 1.00 – 0.85 (m, 1H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 173.5, 161.8, 141.9, 141.8, 134.9, 132.4, 129.6, 129.1, 128.5, 128.0, 127.8, 127.5, 125.7, 122.0, 71.5, 47.6, 41.7, 30.8, 29.6, 24.9, 22.4, 20.2; HRMS (ESI) m/z $[M+H]^+$: Calcd for $\text{C}_{23}\text{H}_{23}\text{NO}_3$: 362.1751. Found: 362.1759.

2',4'-Dichloro-6'-oxo-11',11*a*'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylic acid (*anti/syn*-10e). The title compound was prepared according to general procedure 2 (1 mmol scale). The product was obtained as beige solid, yield 275 mg, 66% (*anti/syn* 0.8:1).

Single isomers of **10e** and compound **13e** were obtained via mechanical separation of monocrystals formed from the same reaction carried out without stirring (reaction conditions: 70 mg (0.28 mmol) of indolenine **9e**, 45 mg (0.28 mmol) of HPA, 2.55 mL MeCN, 5 °C, 48 h).

(*RS,RS*)-2',4'-Dichloro-6'-oxo-11',11*a*'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylic acid (*anti*-10e). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.25 (s, 1H), 8.03 (d, $J=7.3$, 1H), 7.68 – 7.60 (m, 2H), 7.58 – 7.51 (m, 2H), 7.47 (t, $J=7.5$, 1H), 4.45 (d, $J=2.5$, 1H), 4.38 (d, $J=2.7$, 1H), 2.00 – 1.84 (m, 1H), 1.81 – 1.64 (m, 4H), 1.40 (s, 1H), 1.31 – 1.15 (m, 3H), 0.94 (d, $J=5.3$, 1H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 173.2, 161.8, 146.3, 140.0, 135.0, 132.9, 130.5, 128.9, 128.0, 127.7, 127.7, 127.3, 126.3, 123.6, 71.8, 49.0, 41.4, 30.0, 29.3, 24.6, 22.1, 20.0; HPLC-MS-ESI m/z $[M+H]^+$: Calcd for $\text{C}_{22}\text{H}_{19}\text{Cl}_2\text{NO}_3$: 416.0815. Found: 416.0818.

(*RS,SR*)-2',4'-Dichloro-6'-oxo-11',11*a*'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylic acid (*syn*-10e). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.02 (d, $J=7.1$, 1H), 7.61 (td, $J=7.5, 1.2$, 1H), 7.57 – 7.48 (m, 2H), 7.40 (d, $J=1.9$, 1H), 7.33 (d, $J=1.9$, 1H), 4.69 (d, $J=2.8$, 1H), 4.26 (d, $J=2.7$, 1H), 2.09 – 1.96 (m, 1H), 1.89 – 1.33 (m, 9H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 171.6, 160.3, 146.1, 138.0, 137.4, 132.5, 130.1, 129.0, 128.3, 128.2, 128.1, 127.2, 122.0, 119.3, 70.2, 46.7, 45.9, 41.2, 31.0, 24.5, 23.1, 21.6; HPLC-MS-ESI m/z $[M+H]^+$: Calcd for $\text{C}_{22}\text{H}_{19}\text{Cl}_2\text{NO}_3$: 416.0815. Found: 416.0818.

(*SR*)-4-((*RS*)-5',7'-Dichlorospiro[cyclohexane-1,3'-indolin]-2'-yl)isochroman-1,3-dione (13e**).** ^1H NMR (500 MHz, 4% $\text{Me}_2\text{CO}-d_6$ in CDCl_3 ; 5 °C) δ 8.18 (d, $J=7.7$, 1H), 7.74 (t, $J=7.5$, 1H), 7.54 (t, $J=7.6$, 1H), 7.37 (d, $J=7.7$, 1H), 7.03 (s, 1H), 6.87 (s, 1H), 4.28 (s, 1H), 4.19 (s, 1H), 3.78 (s, 1H), 2.79 – 2.67 (m, 1H), 2.06 – 1.94 (m, 1H), 1.84 – 1.72 (m, 1H), 1.69 – 1.50 (m, 4H), 1.50 – 1.36 (m, 2H), 1.29 – 1.12 (m, 1H); ^{13}C NMR (126 MHz, 4% $\text{Me}_2\text{CO}-d_6$ in CDCl_3 ; 5 °C) δ 166.1, 160.8, 142.3, 140.6, 137.9, 135.6, 130.3, 128.8, 127.4, 127.0, 125.4, 123.5, 121.2, 117.2, 71.8, 51.2, 47.3, 38.6, 28.5, 25.5, 23.8, 22.7;

Methyl (11'*RS*,11a'*RS*)-2',4'-dichloro-6'-oxo-11',11a'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylate (*anti*-10e'). The title compound was prepared *via* esterification of *anti/syn*-10e mixture (700 mg, 1.67 mmol, *anti/syn* 1:1) according to general procedure 3 and column chromatography. Yield 534 mg, 75%. Yellow foam. ¹H NMR (400 MHz, CDCl₃) δ 8.26 (dd, *J*=7.8, 1.3, 1H), 7.55 (td, *J*=7.5, 1.4, 1H), 7.51 (d, *J*=1.9, 1H), 7.46 (t, *J*=7.3, 1H), 7.38 (d, *J*=1.9, 1H), 7.34 (d, *J*=7.7, 1H), 4.43 (d, *J*=4.9, 1H), 4.26 (d, *J*=4.9, 1H), 3.83 (s, 3H), 2.04 – 1.73 (m, 4H), 1.67 – 1.15 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 172.3, 161.7, 145.7, 139.4, 133.5, 132.8, 131.3, 129.0, 128.7, 128.5, 127.4, 126.9, 123.7, 71.5, 52.2, 49.4, 42.9, 31.5, 30.0, 25.5, 22.9, 20.5; HRMS (ESI) *m/z* [M-H]⁻: Calcd for C₂₃H₂₁Cl₂NO₃: 428.0826. Found: 428.0833.

1'-(Methylsulfonyl)-6-oxo-11,11a-dihydro-6*H*-spiro[indolo[1,2-*b*]isoquinoline-12,4'-piperidine]-11-carboxylic acid (*anti/syn*-10f). The title compound was prepared according to general procedure 2 (1 mmol scale). White solid, yield 325 mg, 79% (*anti/syn* 2:1). This diastereomeric mixture was separated after esterification according to general procedure 3 and column chromatography (hexane-Me₂CO-DCM 6:2:1 to 4:2:1).

(*RS,RS*)-Methyl 1'-(methylsulfonyl)-6-oxo-11,11a-dihydro-6*H*-spiro-[indolo[1,2-*b*]isoquinoline-12,4'-piperidine]-11-carboxylate (*anti*-10f'). White solid. Yield 191 mg, 41%. Mp 205–207 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J*=7.9, 1H), 8.24 (dd, *J*=7.7, 1.3, 1H), 7.64 – 7.51 (m, 2H), 7.48 (t, *J*=7.5, 1H), 7.41 – 7.30 (m, 1H), 7.19 – 6.99 (m, 2H), 4.48 (d, *J*=12.9, 1H), 4.38 (d, *J*=12.8, 1H), 3.99 (s, 3H), 3.90 – 3.82 (m, 1H), 3.81 – 3.72 (m, 1H), 3.57 (ddd, *J*=13.0, 10.1, 6.0, 1H), 3.17 (td, *J*=12.5, 2.1, 1H), 2.92 (s, 3H), 2.25 (td, *J*=12.7, 4.5, 1H), 2.09 – 1.98 (m, 2H), 1.69 (d, *J*=13.1, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 172.0, 161.9, 141.3, 136.5, 135.1, 133.1, 129.0, 129.0, 128.8, 128.6, 125.6, 124.8, 124.1, 117.7, 68.6, 53.0, 46.6, 44.6, 42.8, 41.0, 36.5, 33.6, 31.3; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₃H₂₄N₂O₅S: 463.1298. Found: 463.1310.

(*RS,SR*)-Methyl 1'-(methylsulfonyl)-6-oxo-11,11a-dihydro-6*H*-spiro-[indolo[1,2-*b*]isoquinoline-12,4'-piperidine]-11-carboxylate (*syn*-10f'). White solid. Yield 102 mg, 22%. Mp 225–226 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.42 (d, *J*=8.0, 1H), 8.26 – 8.10 (m, 1H), 7.56 – 7.46 (m, 2H), 7.44 – 7.38 (m, 1H), 7.37 – 7.29 (m, 2H), 7.09 (t, *J*=7.4, 1H), 4.50 (d, *J*=2.5, 1H), 4.03 (d, *J*=2.9, 1H), 3.73 – 3.59 (m, 2H), 3.47 – 3.24 (m, 5H), 2.91 (s, 3H), 2.15 (t, *J*=5.5, 2H), 1.97 (t, *J*=5.3, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 170.6, 136.4, 135.5, 132.7, 129.4, 129.3, 129.1, 127.5, 124.0, 123.3, 116.3, 69.5, 52.8, 46.4, 44.4, 43.1, 42.5, 40.1, 35.9, 31.6; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₃H₂₄N₂O₅S: 463.1298. Found: 463.1318.

(*RS,RS*)- and (*RS,SR*)-Methyl 12,12-dimethyl-6-oxo-6,11,11a,12-tetrahydroindolo[1,2-*b*]isoquinoline-11-carboxylates (*anti*- and *syn*-10g'). A mixture of phenylhydrazine hydrochloride (433 mg, 3 mmol) and isobutyric aldehyde (216 mg, 3 mmol) in 15 ml of glacial acetic acid was heated at 50 °C for 2 h in a sealed screw-cap vial. Next, the reaction mixture was gradually poured into ca. 100 ml of saturated aqueous NaHCO₃ and extracted with five 2 ml portions of CHCl₃. Combined organic extracts were washed with brine, dried over MgSO₄, filtered and used without purification. Solution of 3,3-dimethylindolenine (NMR yield 1.75 mmol, 58%) was placed in a 15 ml screw-cap vial followed by addition of homophthalic anhydride (284 mg, 1.75 mmol). The reaction mixture was stirred at room temperature for 16 h, concentrated *in vacuo* and redissolved in Me₂CO (12 mL). Methyl iodide (284 mg, 2 mmol) and K₂CO₃ (276 mg, 2 mmol) were added to the solution and stirred for 24 h at r.t. The volatiles were removed *in vacuo*, CHCl₃

and water were added to the residue. The organic layer was separated, washed with brine, dried over Na₂SO₄ and concentrated to give crude mixture of *anti*- and *syn*-**10g'**. Column chromatography (hexane-Me₂CO from 7:1 to 4:1) afforded pure isomers.

Anti-10g': Yield 286 mg, 51%. Yellow foam. ¹H NMR (400 MHz, CDCl₃) δ 8.42 (d, *J*=8.0, 1H), 8.26 (dd, *J*=7.6, 1.2, 1H), 7.58 – 7.35 (m, 2H), 7.34 – 7.25 (m, 1H), 7.21 (d, *J*=6.9, 1H), 7.16 – 6.98 (m, 2H), 4.49 (d, *J*=13.0, 1H), 4.33 (d, *J*=12.9, 1H), 3.94 (s, 3H), 1.43 (s, 3H), 1.27 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) 172.0, 161.8, 140.3, 140.1, 135.4, 132.8, 129.4, 128.8, 128.4, 128.3, 125.4, 124.8, 121.9, 116.9, 68.9, 52.6, 47.0, 43.6, 26.3, 25.0; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₀H₁₉NO₃: 322.1438. Found: 322.1439.

Syn-10g': Yield 202 mg, 36%. Yellow foam. ¹H NMR (400 MHz, CDCl₃) δ 8.40 (d, *J*=8.0, 1H), 8.30 – 8.09 (m, 1H), 7.53 – 7.45 (m, 2H), 7.42 – 7.36 (m, 1H), 7.32 – 7.27 (m, 1H), 7.18 (dd, *J*=7.4, 0.8, 1H), 7.10 (td, *J*=7.4, 0.9, 1H), 4.37 (d, *J*=3.7, 1H), 4.05 (d, *J*=3.7, 1H), 3.50 (s, 1H), 1.50 (s, 2H), 1.32 (s, 2H); ¹³C NMR (101 MHz, CDCl₃) 171.4, 162.2, 141.1, 139.5, 135.7, 132.4, 130.9, 129.3, 129.1, 128.3, 127.4, 124.3, 122.0, 116.5, 70.0, 52.6, 46.0, 43.5, 30.5, 25.1; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₀H₁₉NO₃: 322.1438. Found: 322.1445.

11a,12,12-Trimethyl-6-oxo-6,11,11a,12-tetrahydroindolo[1,2-*b*]isoquinoline-11-carboxylic acid (*anti/syn*-10h**)**. The title compound was prepared after evaporation of reaction mixture obtained according to general procedure 2 (1.9 mmol scale) and washing the residue with hexane-CCl₄ 1:1 mixture. The product was obtained as white solid. Yield 520 mg, 86% (*anti/syn* 4.3:1). Crystallization from MeCN gave **9h** as a single diastereomer. Mp 270–271 °C (decomp.); ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.59 (s, 1H), 8.26 (d, *J*=7.8, 1H), 8.08 (dd, *J*=7.7, 1.1, 1H), 7.66 (td, *J*=7.6, 1.3, 1H), 7.52 (t, *J*=7.5, 1H), 7.34 (d, *J*=7.3, 1H), 7.30 – 7.22 (m, 2H), 7.15 (td, *J*=7.4, 0.9, 1H), 4.63 (s, 1H), 1.41 (s, 3H), 1.31 (s, 3H), 1.13 (s, 3H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 171.9, 161.0, 140.5, 138.3, 135.8, 132.8, 128.6, 127.7, 127.6, 127.6, 126.1, 124.5, 122.2, 116.2, 70.9, 49.5, 47.0, 27.1, 20.3, 17.2; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₀H₁₉NO₃: 322.1438. Found: 322.1440.

2-Fluoro-11a,12,12-trimethyl-6-oxo-6,11,11a,12-tetrahydro-indolo[1,2-*b*]isoquinoline-11-carboxylic acid (*anti/syn*-10i**)**. The title compound was prepared according to general procedure 2 (1 mmol scale) as a 3:1 mixture of diastereomers. Yield 244 mg, 72%; Diastereomers were separated after esterification according to general procedure 3 and column chromatography (hexane-Me₂CO 6:1 to 4:1).

(*RS,RS*)-Methyl 2-fluoro-11a,12,12-trimethyl-6-oxo-6,11,11a,12-tetrahydroindolo[1,2-*b*]isoquinoline-11-carboxylate (*anti*-10i'**)**. White foam, yield 166 mg, 47% (for two steps); ¹H NMR (400 MHz, CDCl₃) δ 8.37 (dd, *J*=8.8, 4.9, 1H), 8.23 (dd, *J*=7.6, 1.4, 1H), 7.53 (td, *J*=7.5, 1.5, 1H), 7.46 (t, *J*=7.5, 1H), 7.05 (d, *J*=7.6, 1H), 6.96 (td, *J*=8.9, 2.7, 1H), 6.89 (dd, *J*=8.1, 2.6, 1H), 4.65 (s, 1H), 3.95 (s, 3H), 1.36 (s, 3H), 1.34 (s, 3H), 1.27 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 171.4, 161.8, 160.3 (d, *J*_{CF}=243.4), 142.7 (d, *J*_{CF}=7.5), 135.2, 134.9 (d, *J*_{CF}=2.1), 132.8, 128.9, 128.7, 128.1, 126.1, 118.6 (d, *J*_{CF}=8.1), 114.4 (d, *J*_{CF}=22.8), 109.3 (d, *J*_{CF}=24.2), 72.1, 52.4, 50.1, 47.6 (d, *J*_{CF}=1.6), 27.4, 20.4, 17.4; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₁H₂₀FNO₃: 354.1492. Found: 354.1500.

(RS,SR)-Methyl 2-fluoro-11a,12,12-trimethyl-6-oxo-6,11,11a,12-tetrahydroindolo[1,2-b]isoquinoline-11-carboxylate (syn-10i'). White foam, yield 46 mg, 13% (for two steps); ¹H NMR (400 MHz, CDCl₃) δ 8.39 (dd, *J*=8.8, 4.9, 1H), 8.25 (dd, *J*=6.4, 2.5, 1H), 7.54 – 7.41 (m, 2H), 7.39 – 7.29 (m, 1H), 6.96 (td, *J*=8.9, 2.6, 1H), 6.86 (dd, *J*=8.1, 2.6, 1H), 3.96 (s, 1H), 3.52 (s, 3H), 1.49 (s, 3H), 1.27 (s, 3H), 1.12 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 172.2, 162.1, 160.1 (d, *J*_{CF}=242.7), 141.8 (d, *J*_{CF}=7.4), 135.9, 135.7 (d, *J*_{CF}=1.9), 132.5, 129.7, 129.4, 128.8, 127.5, 118.2 (d, *J*_{CF}=8.0), 114.4 (d, *J*_{CF}=22.7), 109.2 (d, *J*_{CF}=24.2), 70.8, 52.6, 51.7, 48.1 (d, *J*_{CF}=1.6), 28.2, 23.9, 21.9; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₁H₂₀FN₃O₃: 354.1492. Found: 354.1499.

(RS,RS)-11a,12,12-Trimethyl-2-nitro-6-oxo-6,11,11a,12-tetrahydro-indolo[1,2-b]isoquinoline-11-carboxylic acid (anti-10j). The title compound was prepared according to general procedure 2 (1 mmol scale). The product was obtained as light yellow solid, mp 294–296 °C (decomp.). Yield 268 mg, 73%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.70 (s, 1H), 8.42 (d, *J* = 8.8 Hz, 1H), 8.32 – 8.16 (m, 2H), 8.11 (dd, *J* = 7.7, 1.1 Hz, 1H), 7.70 (td, *J* = 7.6, 1.4 Hz, 1H), 7.54 (t, *J* = 7.6 Hz, 1H), 7.27 (d, *J* = 7.7 Hz, 1H), 4.75 (s, 1H), 1.49 (s, 3H), 1.38 (s, 3H), 1.18 (s, 3H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 171.67, 161.8, 143.9, 143.8, 142.1, 136.1, 133.5, 128.1, 127.9, 127.8, 126.3, 124.9, 118.3, 116.0, 72.1, 49.2, 47.1, 26.7, 19.9, 17.4; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₀H₁₈N₂O₅: 367.1288. Found: 367.1296.

2-Hydroxy-11a,12,12-trimethyl-6-oxo-6,11,11a,12-tetrahydro-indolo[1,2-b]isoquinoline-11-carboxylic acid (anti/syn-10k). The title compound was prepared according to general procedure 2 (1 mmol scale). The product was obtained as a white solid. Yield 192 mg, 57% (*anti/syn* 6.5:1). Crystallization from MeCN gave pure *anti*-isomer for analysis. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.54 (s, 1H), 9.33 (s, 1H), 8.16 – 7.98 (m, 2H), 7.62 (td, *J* = 7.6, 1.3 Hz, 1H), 7.49 (t, *J* = 7.5 Hz, 1H), 7.22 (d, *J* = 7.7 Hz, 1H), 6.71 (d, *J* = 2.4 Hz, 1H), 6.64 (dd, *J* = 8.6, 2.4 Hz, 1H), 4.56 (s, 1H), 1.35 (s, 3H), 1.29 (s, 3H), 1.11 (s, 4H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ = 172.0, 160.0, 154.7, 142.1, 135.5, 132.4, 130.5, 128.7, 127.5, 127.4, 126.0, 117.2, 113.5, 109.2, 70.9, 49.6, 47.0, 27.0, 20.2, 17.1; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₀H₁₉NO₄: 338.1387. Found: 338.1397.

(4aRS,15SR,15aSR)-4a-Methyl-10-oxo-2,3,4,4a,10,15-hexahydro-1H-isoquinolino[3,2-*k*]carbazole-15-carboxylic acid (anti-10l). The title compound was prepared according to general procedure 2 (1 mmol scale). The product was obtained as white solid, mp 253–255 °C (decomp.). Yield 280 mg, 81%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.59 (s, 1H), 8.32 (d, *J*=7.6, 1H), 8.07 (dd, *J*=7.7, 1.2, 1H), 7.63 (td, *J*=7.6, 1.4, 1H), 7.49 (t, *J*=7.5, 1H), 7.38 – 7.21 (m, 3H), 7.16 (td, *J*=7.4, 1.0, 1H), 4.68 (s, 1H), 2.25 – 2.13 (m, 2H), 1.74 (td, *J*=13.8, 4.0, 1H), 1.57 – 1.42 (m, 3H), 1.33 (s, 3H), 1.20 – 1.03 (m, 4H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 172.4, 161.2, 139.4, 138.9, 135.7, 132.6, 128.5, 127.6, 127.5, 124.5, 122.1, 116.8, 69.8, 49.4, 47.8, 30.6, 30.0, 27.2, 20.8, 20.2; HRMS (ESI) *m/z* [M+H]⁺: Calcd for C₂₂H₂₁NO₃: 370.1414. Found: 370.1421.

11a-Methyl-6-oxo-2',3',5',6',11,11a-hexahydro-6H-spiro-[indolo[1,2-b]isoquinoline-12,4'-pyran]-11-carboxylic acid (anti/syn-10m). The title compound was prepared according to general procedure 2 (1.4 mmol scale). The product was obtained as white solid, mp 252–254 °C. Yield 436 mg, 79% (*anti/syn* = 6:1). Crystallization from MeCN gave *anti*-10m as a single isomer (289 mg, 52%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.72 (s, 1H), 8.42 (d, *J*=7.8, 1H), 8.08 (dd, *J*=7.6, 0.9, 1H), 7.87 (d, *J*=7.5, 1H), 7.67 (td, *J*=7.6, 1.2, 1H), 7.52 (t, *J*=7.5, 1H), 7.32 (t, *J*=7.5, 1H), 7.24 (d, *J*=7.7, 1H), 7.15 (t, *J*=7.2, 1H), 4.64 (s, 1H), 4.23 (td, *J*=12.4, 2.7, 1H), 3.95 (dd, *J*=12.1, 6.1, 1H), 3.75 – 3.72 (m, 1H), 3.52 (t, *J*=11.5, 1H), 2.36 (td, *J*=12.6, 4.3, 1H), 1.99 (td, *J*=13.2, 6.5, 1H), 1.88

– 1.84 (m, 1H), 1.42 – 1.39 (m, 1H); ^{13}C NMR (101 MHz, DMSO- d_6) δ = 171.8, 161.2, 139.3, 137.5, 135.6, 132.9, 128.4, 127.7, 127.7, 127.7, 125.9, 125.9, 123.6, 116.5, 71.6, 64.0, 62.0, 49.5, 47.8, 32.6, 29.2, 15.7; HRMS (ESI) m/z $[\text{M}+\text{H}]^+$: Calcd for $\text{C}_{22}\text{H}_{21}\text{NO}_4$: 386.1363. Found: 386.1356.


(*RS,RS*)-11*a*'-Methyl-6'-oxo-11',11*a*'-dihydro-6'*H*-spiro[cyclohexane-1,12'-indolo[1,2-*b*]isoquinoline]-11'-carboxylic acid (*anti*-10n). The title compound was prepared according to general procedure 2 (0.9 mmol scale). The product was obtained as white solid, mp 239–241 °C (decomp.). Yield 336 mg, 93%. ^1H NMR (400 MHz, DMSO- d_6) δ 13.65 (s, 1H), 8.38 (d, J =7.4, 1H), 8.07 (dd, J =7.7, 1.1, 1H), 7.71 (d, J =7.4, 1H), 7.65 (td, J =7.6, 1.4, 1H), 7.50 (t, J =7.5, 1H), 7.32 – 7.25 (m, 1H), 7.22 (d, J =7.7, 1H), 7.11 (td, J =7.5, 0.9, 1H), 4.63 (s, 1H), 2.17 – 1.92 (m, 3H), 1.88 – 1.74 (m, 2H), 1.64 (td, J =13.5, 5.5, 1H), 1.52 (d, 2H), 1.42 – 1.28 (m, 1H), 1.24 – 1.13 (m, 1H), 1.09 (s, 3H); ^{13}C NMR (101 MHz, DMSO- d_6) δ 172.1, 161.1, 139.3, 138.5, 135.8, 132.3, 128.4, 127.6, 127.4, 126.1, 126.0, 123.5, 116.4, 71.9, 49.8, 49.3, 32.7, 28.3, 25.1, 22.8, 20.7, 16.2; HRMS (ESI) m/z $[\text{M}+\text{H}]^+$: Calcd for $\text{C}_{23}\text{H}_{23}\text{NO}_3$: 384.1570. Found: 384.1558.

(*RS,SR*)-12,12-Dimethyl-6-oxo-11*a*-(*p*-tolyl)-6,11,11*a*,12-tetrahydroindolo[1,2-*b*]isoquinoline-11-carboxylic acid (*anti*-10o). The title compound was prepared according to general procedure 2 (0.9 mmol scale). The product was obtained as white solid, mp 236–237 °C (decomp.). Yield 208 mg, 52%. ^1H NMR (400 MHz, DMSO- d_6) δ 13.64 (s, 1H), 8.38 (d, J =7.9, 1H), 7.77 (d, J =7.1, 1H), 7.50 (t, J =7.1, 1H), 7.37 – 7.31 (m, 2H), 7.30 – 7.21 (m, 2H), 7.19 – 7.06 (m, 2H), 6.77 (d, J =8.3, 2H), 5.26 (s, 1H), 2.04 (s, 3H), 1.47 (s, 3H), 1.15 (s, 3H); ^{13}C NMR (101 MHz, DMSO- d_6) δ 172.0, 162.5, 141.0, 140.4, 136.7, 136.2, 136.0, 132.4, 129.7, 128.0, 127.9, 127.5, 127.0, 125.27, 124.7, 122.7, 114.7, 77.6, 53.0, 49.0, 28.6, 22.9, 20.2; HRMS (ESI) m/z $[\text{M}+\text{H}]^+$: Calcd for $\text{C}_{26}\text{H}_{23}\text{NO}_3$: 398.1751. Found: 398.1762.

11*a*,12,12-Trimethyl-11*a*,12-dihydroindolo[1,2-*b*]isoquinolin-6(11*H*)-one (14h). Compound *anti/syn*-10h (93 mg, 0.29 mmol, 4.3:1) was dissolved in 1 mL of hexamethylphosphoramide and stirred at 205–210 °C for 1h in air. After complete consumption of starting material (controlled by TLC) the reaction mixture was diluted with 50 mL of EtOAc and washed with 5×20 mL of water. The organic layer was washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure to give pure **14h** (67 mg, 83%). Yellow oil. ^1H NMR (400 MHz, DMSO- d_6) δ 8.22 (d, J =7.8, 1H), 8.03 (dd, J =7.6, 0.9, 1H), 7.56 (td, J =7.4, 1.3, 1H), 7.45 – 7.40 (m, 2H), 7.33 (dd, J =7.4, 0.8, 1H), 7.25 (td, J =7.8, 1.3, 1H), 7.12 (td, J =7.4, 1.0, 1H), 3.43 (d, J =15.6, 1H), 2.99 (d, J =15.7, 1H), 1.40 (s, 3H), 1.16 (s, 3H), 0.97 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 162.4, 140.4, 139.7, 137.1, 132.3, 129.3, 128.4, 128.3, 127.9, 127.2, 124.4, 121.9, 117.4, 69.2, 46.6, 34.3, 28.1, 20.9, 20.2; HRMS (ESI) m/z $[\text{M}+\text{H}]^+$: Calcd for $\text{C}_{19}\text{H}_{19}\text{NO}$: 278.1539. Found: 278.1537.

2. NMR studies for compounds **10d** and **10e**















In order to rationalize the inconsistency between $^3J_{\text{HH}}$ -values and the value of dihedral angle in crystal form for compounds **10d** and **10e** we performed a series of NMR experiments. We reasoned that such a phenomenon could be explained by distorted molecular geometry (see section 5, crystallographic data) and different conformer population in the solution compared to solid state.



For compound **10e** two sets of H-NMR spectra were recorded: at temperatures varying from 293 to 183 K in $\text{Me}_2\text{CO}-d_6$ (mixture *anti/syn* 1:1; Figure S1) and from 293 to 393 K in $\text{DMSO}-d_6$ (*anti-10e*; Figure S2). We observed decoalescence for the signals of H^{11} and H^{11a} atoms for both diastereomers at 223 K (Figure S1) along with new set of signals arising: $\delta_{\text{H}} = 4.56$ and 4.42 ppm. It was not possible to identify these new signals by ^1H -NMR spectrum only, due to their very low intensity, caused by small relative content of corresponding molecules. Nevertheless correlation spectroscopy provided some useful information about these sets of signals. COSY spectrum proved this pair of protons with chemical shifts 4.56 and 4.42 ppm to be a spin system (Figure S3). ROESY spectrum recorded for compound *anti/syn-10e* at 183 K (Figure S4) revealed exchange cross-peaks between this new spin system and spin system of compound *syn-10e* (δ_{H} 4.94 and 4.59 ppm). In addition this ROESY spectrum demonstrated another two exchange cross-peaks (δ_{H} 5.08-4.72 and 4.80-4.51 ppm). The new signals (δ_{H} 5.08 and 4.80 ppm) exchanged with signals of *anti-10e* (δ_{H} 4.72 and 4.51 ppm). These facts may indicate that two new sets of signals observed at low temperatures belong to minor conformers of different isomers of **10e**. In addition we observed variation in $J_{\text{H}^{11}\text{-H}^{11a}}$ coupling constant (*anti-10e*) from 2.6 to 0.7 Hz at temperature decrease (Figure S1) and from 2.9 to 3.7 Hz under heating (Figure S2). In the first case variation can be explained by increasing amount of major (thermodynamically more stable) conformer with small J -value. Variation in the second case correlates with increasing amount of thermodynamically less stable conformer with J -constant about 13 Hz, which is major conformer for all other cases (*anti-*

10a-c,f,g). A similar series of NMR-experiments was carried out for compound *anti-10d* – H-NMR spectra were recorded from 292 to 182K in Me₂CO-*d*₆ (Figure S5) and from 293 to 393K in DMSO-*d*₆ (Figure S6). In this case $J_{H11-H11a}$ coupling constant varied from 3.6 to 1.5 Hz under cooling and from 3.3 to 4.0 Hz under heating. *J*-values were obtained from *J*-resolved experiments.

TableS1. Measured dihedral angles for C¹¹H-C^{11a}H fragments for compounds **10** and corresponding ³*J*- coupling constants.

Compound	Angle ^a C ¹¹ H-C ^{11a} H, °	$J_{C^{11}H-C^{11a}H}$, Hz	Compound	Angle ^a C ¹¹ H-C ^{11a} H, °	$J_{C^{11}H-C^{11a}H}$, Hz
 <i>anti-10g'</i>	168.7	13.0	 <i>anti-10e'</i>	94.2	4.8
 <i>syn-10g'</i>	ND	3.7	 <i>anti-10e</i>	166.7	2.6
 <i>anti-10a'</i>	164.7	13.0 (12.9, for corresponding acid)	 <i>syn-10e</i>	57.5	2.8
 <i>syn-10a'</i>	58.1	3.2 (3.0, for corresponding acid)	 <i>anti-10d</i>	169.3	3.3
 <i>anti-10c</i>	169.9	13.6	 <i>anti-10f'</i>	171.6	12.9 (12.8, for corresponding acid)
 <i>syn-10c</i>	ND	2.8	 <i>syn-10f'</i>	55.5	2.9 (3.2, for corresponding acid)
 <i>anti-10b</i>	170.3	12.9	 <i>syn-10b'</i>	ND	3.3

^a Data obtained from X-ray single crystal analysis




Figure S1: Fragments of H-NMR spectra of compound **10e** (*anti/syn* 1:1) at 293 K (top) – 183 K (bottom) in $\text{Me}_2\text{CO}-d_6$.




Figure S2: Fragments of H-NMR spectra of compound *anti*-**10e** at 393K (top) – 293K (bottom) in $\text{DMSO}-d_6$.




Figure S3: Fragment of COSY spectrum for compound **10e** (*anti/syn* 1:1) at 183K in Me₂CO-*d*₆




Figure S4: Fragment of ROESY spectrum for compound **10e** (*anti*/*syn* 1:1) at 183K in Me₂CO-*d*₆ with different contour levels




Figure S5: Fragments of H-NMR spectra of compound *anti*-**10d** at 293 K (top) – 183 K (bottom) in $\text{Me}_2\text{CO}-d_6$




Figure S6: Fragments of H-NMR spectra of compound *anti*-**10d** at 393K (top) – 293K (bottom) in $\text{DMSO}-d_6$

3. Relative configuration determination for compounds **10k** and **10m**

^{13}C NMR spectra of **10h–k,m,n** major isomers revealed chemical shifts of carbon atom in CH_3^{11a} -group to be about 16–17 ppm, while for minor isomers of **10h–k** these chemical shifts lie within 23–24 ppm (Table S2). According to X-ray major isomers of **10h–i,n** have *anti*-configuration. Thus the values of ^{13}C chemical shifts of CH_3^{11a} -groups can serve as criterion for relative configuration assignment in CCR products **10**, derived from 2-methylindolenines. The configuration of **10k** and **10m** major isomers was determined to be *anti*- according to this criterion: $\delta\text{C}(\text{CH}_3^{11a}) = 17.1$ and 15.7 ppm respectively.











Table S2. ^{13}C chemical shifts δ , ppm of C^{11a} -methyl group for compounds **10**.

Compound	$\delta\text{C}^{11a-\text{Me}}$ (<i>anti</i> -)	$\delta\text{C}^{11a-\text{Me}}$ (<i>syn</i> -)	Compound	$\delta\text{C}^{11a-\text{Me}}$ (<i>anti</i> -)	$\delta\text{C}^{11a-\text{Me}}$ (<i>syn</i> -)
 10h	17.2	23.4	 10k	17.1	23.9
 10i	17.7	23.8	 10m	15.7	-
 10j	17.4	23.3	 10n	16.2	-

4. Relative configuration determination for compound **10o**

Relative configuration of 11a-(*p*-tolyl)-substituted compound **10o** was assigned to be (*RS*, *SR*)- on the basis of NOESY spectrum, which showed one cross peak from *ortho*-protons of *p*-tolyl moiety to methyl group in position 12 and another cross peak from H^{11} to the second methyl group in position 12. The value of observed coupling constant between $\text{C}_{\text{ipso}}(\textit{p}\text{-tolyl})$ and H^{11} $^3J_{\text{CH}}$ 6.3 Hz also confirms this assignment (expected value of $^3J_{\text{CH}}$ for staggered conformation of $\text{C}^{\text{ipsoAr}}\text{--C}^{11a}\text{--C}^{11}\text{--H}^{11}$ fragment (*anti*-isomer) is 6–8 Hz and 1–3 Hz for *gauche*-conformation (*syn*-isomer); Figure S7–9) [11,12].






Figure S7 Measured coupling constants J_{C-H}^{11} for compound **10o**.




Figure S8 Reported values of coupling constants $^3J_{C-H}$ and $^2J_{C-H}$ for systems with β -heteroatom¹.






Figure S9 Calculated dihedral angles (MM2; ChemBioOffice 2014) for *anti*- and *syn*-isomers of compound **10o**.

5. Crystallographic data for compounds 10 and 13e.

X-ray single crystal analyses were performed on Agilent Technologies «Xcalibur» and «Supernova» diffractometers with monochromated Mo K α or Cu K α radiation, respectively. Crystals were measuring at the temperature of 100 K for all samples, except *anti*-**10f'**, which destroyed at lower temperature. The structures has been solved by the Superflip [13] and ShelXS [14] structure solution programs using Charge Flipping and Direct Methods, respectively, and refined with the ShelXL [15] refinement incorporated in the OLEX2 program package [16]. The structure *anti*-**10e'** contains disordered DMSO on threefold axis. Electron density from this solvent has been suppressed using SQUEEZE/PLATON [17] program. CCDC 1503093-1503106, 1470399, 1470389, 1461790 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <http://www.ccdc.cam.ac.uk>.




anti-**10e**




syn-**10e**

Table S3 Crystal data and structure refinement for <i>anti</i> - 10e		Table S4 Crystal data and structure refinement for <i>syn</i> - 10e	
Empirical formula	C ₂₂ H ₁₉ Cl ₂ NO ₃	Empirical formula	C ₂₂ H ₁₉ Cl ₂ NO ₃
Formula weight	416.28	Formula weight	416.28
Temperature/K	100(2)	Temperature/K	100(2)
Crystal system	monoclinic	Crystal system	orthorhombic
Space group	P2 ₁ /c	Space group	P2 ₁ 2 ₁ 2 ₁
a/Å	15.7357(3)	a/Å	9.8687(3)
b/Å	6.94798(11)	b/Å	12.2841(4)
c/Å	17.1351(3)	c/Å	15.4822(5)
α /°	90	α /°	90
β /°	101.9535(17)	β /°	90
γ /°	90	γ /°	90
Volume/Å ³	1832.78(5)	Volume/Å ³	1876.88(11)
Z	4	Z	4
ρ_{calc} /g/cm ³	1.509	ρ_{calc} /g/cm ³	1.473
μ /mm ⁻¹	0.379	μ /mm ⁻¹	0.370
F(000)	864.0	F(000)	864.0
Crystal size/mm ³	0.25 × 0.25 × 0.2	Crystal size/mm ³	0.25 × 0.25 × 0.2
Radiation	MoK α (λ = 0.71073)	Radiation	MoK α (λ = 0.71073)
2 θ range for data	5.996 to 54.99	2 θ range for data	5.914 to 54.99

collection/°		collection/°	
Index ranges	$-20 \leq h \leq 20, -9 \leq k \leq 9, -22 \leq l \leq 22$	Index ranges	$-12 \leq h \leq 11, -15 \leq k \leq 15, -20 \leq l \leq 20$
Reflections collected	32039	Reflections collected	18673
Independent reflections	4193 [$R_{\text{int}} = 0.0240, R_{\text{sigma}} = 0.0133$]	Independent reflections	4312 [$R_{\text{int}} = 0.0274, R_{\text{sigma}} = 0.0240$]
Data/restraints/parameters	4193/0/254	Data/restraints/parameters	4312/0/254
Goodness-of-fit on F^2	1.046	Goodness-of-fit on F^2	1.047
Final R indexes [$I \geq 2\sigma(I)$]	$R_1 = 0.0340, wR_2 = 0.0841$	Final R indexes [$I \geq 2\sigma(I)$]	$R_1 = 0.0265, wR_2 = 0.0647$
Final R indexes [all data]	$R_1 = 0.0372, wR_2 = 0.0867$	Final R indexes [all data]	$R_1 = 0.0288, wR_2 = 0.0664$
Largest diff. peak/hole / $e \text{ \AA}^{-3}$	0.48/-0.22	Largest diff. peak/hole / $e \text{ \AA}^{-3}$	0.32/-0.19
CCDC	1503097	CCDC	1503105




anti-10e'



13e

Table S5 Crystal data and structure refinement for <i>anti-10e'</i>		Table S6 Crystal data and structure refinement for 13e	
Empirical formula	$C_{23}H_{21}Cl_2NO_3$	Empirical formula	$C_{22}H_{19}Cl_2NO_3$
Formula weight	430.31	Formula weight	416.28
Temperature/K	100(2)	Temperature/K	100(2)
Crystal system	trigonal	Crystal system	monoclinic
Space group	R3	Space group	$P2_1/c$
a/Å	20.4043(3)	a/Å	16.3985(8)
b/Å	20.4043(3)	b/Å	11.1961(6)
c/Å	13.6622(2)	c/Å	10.3370(5)
$\alpha/^\circ$	90	$\alpha/^\circ$	90
$\beta/^\circ$	90	$\beta/^\circ$	96.103(5)
$\gamma/^\circ$	120	$\gamma/^\circ$	90
Volume/Å ³	4926.02(15)	Volume/Å ³	1887.11(16)
Z	9	Z	4
$\rho_{\text{calc}}/\text{g cm}^{-3}$	1.305	$\rho_{\text{calc}}/\text{g cm}^{-3}$	1.465
μ/mm^{-1}	2.859	μ/mm^{-1}	3.297
F(000)	2016.0	F(000)	864.0
Crystal size/mm ³	$0.3 \times 0.2 \times 0.2$	Crystal size/mm ³	$0.2 \times 0.08 \times 0.08$
Radiation	$\text{CuK}\alpha$ ($\lambda = 1.54184$)	Radiation	$\text{CuK}\alpha$ ($\lambda = 1.54184$)
2 θ range for data collection/°	8.18 to 144.976	2 θ range for data collection/°	9.582 to 144.898
Index ranges	$-25 \leq h \leq 25, -22 \leq k \leq 25,$	Index ranges	$-20 \leq h \leq 20, -13 \leq k$


	-16 ≤ l ≤ 16		≤ 9, -11 ≤ l ≤ 12
Reflections collected	16404	Reflections collected	7750
Independent reflections	4288 [$R_{\text{int}} = 0.1334$, $R_{\text{sigma}} = 0.0628$]	Independent reflections	3725 [$R_{\text{int}} = 0.0521$, $R_{\text{sigma}} = 0.0614$]
Data/restraints/parameters	4288/1/263	Data/restraints/parameters	3725/0/253
Goodness-of-fit on F^2	1.117	Goodness-of-fit on F^2	1.040
Final R indexes [$I \geq 2\sigma(I)$]	$R_1 = 0.0450$, $wR_2 = 0.1109$	Final R indexes [$I \geq 2\sigma(I)$]	$R_1 = 0.0583$, $wR_2 = 0.1554$
Final R indexes [all data]	$R_1 = 0.1433$, $wR_2 = 0.1639$	Final R indexes [all data]	$R_1 = 0.0676$, $wR_2 = 0.1680$
Largest diff. peak/hole / $e \text{ \AA}^{-3}$	0.84/-0.64	Largest diff. peak/hole / $e \text{ \AA}^{-3}$	0.66/-0.45
CCDC	1503102	CCDC	1503093



Crystal structure determination of *anti*-10n

Crystal Data for $C_{23}H_{23}NO_3$ ($M = 361.42$ g/mol): monoclinic, space group $C2/c$ (no. 15), $a = 23.3057(6)$ Å, $b = 12.7914(3)$ Å, $c = 16.7508(4)$ Å, $\beta = 133.0560(10)^\circ$, $V = 3648.77(16)$ Å³, $Z = 8$, $T = 100(2)$ K, $\mu(\text{MoK}\alpha) = 0.087$ mm⁻¹, $D_{\text{calc}} = 1.316$ g/cm³, 30249 reflections measured ($6.15^\circ \leq 2\theta \leq 54.996^\circ$), 4190 unique ($R_{\text{int}} = 0.0207$, $R_{\text{sigma}} = 0.0109$) which were used in all calculations. The final R_1 was 0.0366 ($I > 2\sigma(I)$) and wR_2 was 0.0998 (all data).


CCDC 1503103



Crystal structure determination of *syn*-10a'

Crystal Data for $C_{23}H_{23}NO_3$ ($M = 361.42$ g/mol): triclinic, space group $P-1$ (no. 2), $a = 11.5749(2)$ Å, $b = 12.2804(4)$ Å, $c = 13.7928(4)$ Å, $\alpha = 68.362(3)^\circ$, $\beta = 88.617(2)^\circ$, $\gamma = 81.872(2)^\circ$, $V = 1803.27(9)$ Å³, $Z = 4$, $T = 100(2)$ K, $\mu(\text{CuK}\alpha) = 0.703$ mm⁻¹, $D_{\text{calc}} = 1.331$ g/cm³, 51248 reflections measured ($6.898^\circ \leq 2\theta \leq 152.6^\circ$), 7555 unique ($R_{\text{int}} = 0.0531$, $R_{\text{sigma}} = 0.0235$) which were used in all calculations. The final R_1 was 0.0374 ($I > 2\sigma(I)$) and wR_2 was 0.0977 (all data).


CCDC 1503100



Crystal structure determination of *anti*-10g'

Crystal Data for $C_{20}H_{19}NO_3$ ($M = 321.36$ g/mol): monoclinic, space group Cc (no. 9), $a = 17.7696(7)$ Å, $b = 13.3575(5)$ Å, $c = 7.1549(3)$ Å, $\beta = 109.372(3)^\circ$, $V = 1602.12(11)$ Å³, $Z = 4$, $T = 100(2)$ K, $\mu(\text{MoK}\alpha) = 0.090$ mm⁻¹, $D_{\text{calc}} = 1.332$ g/cm³, 7519 reflections measured ($6.1^\circ \leq 2\theta \leq 54.986^\circ$), 3473 unique ($R_{\text{int}} = 0.0281$, $R_{\text{sigma}} = 0.0387$) which were used in all calculations. The final R_1 was 0.0370 ($I > 2\sigma(I)$) and wR_2 was 0.0926 (all data).


CCDC 1503096



Crystal structure determination of *anti*-10l

Crystal Data for $C_{22}H_{21}NO_3$ ($M = 347.40$ g/mol): monoclinic, space group $C2/c$ (no. 15), $a = 22.5031(6)$ Å, $b = 13.5761(4)$ Å, $c = 14.7923(4)$ Å, $\beta = 129.571(2)^\circ$, $V = 3483.49(18)$ Å³, $Z = 8$, $T = 100(2)$ K, $\mu(\text{MoK}\alpha) = 0.088$ mm⁻¹, $D_{\text{calc}} = 1.325$ g/cm³, 29448 reflections measured ($5.51^\circ \leq 2\theta \leq 54.998^\circ$), 4001 unique ($R_{\text{int}} = 0.0713$, $R_{\text{sigma}} = 0.0318$) which were used in all calculations. The final R_1 was 0.0410 ($I > 2\sigma(I)$) and wR_2 was 0.1107 (all data).


CCDC 1503106



Crystal structure determination of *anti*-10i

Crystal Data for $C_{21}H_{20}FNO_3$ ($M = 353.38$ g/mol): monoclinic, space group $C2/c$ (no. 15), $a = 26.5832(15)$ Å, $b = 6.7549(2)$ Å, $c = 21.1207(8)$ Å, $\beta = 115.042(3)^\circ$, $V = 3436.1(3)$ Å³, $Z = 8$, $T = 100(2)$ K, $\mu(\text{MoK}\alpha) = 0.098$ mm⁻¹, $D_{\text{calc}} = 1.366$ g/cm³, 15007 reflections measured ($6.264^\circ \leq 2\theta \leq 54.994^\circ$), 3943 unique ($R_{\text{int}} = 0.0255$, $R_{\text{sigma}} = 0.0244$) which were used in all calculations. The final R_1 was 0.0371 ($I > 2\sigma(I)$) and wR_2 was 0.0945 (all data).


CCDC 1503104



Crystal structure determination of *syn*-10f

Crystal Data for $C_{23}H_{24}N_2O_5S$ ($M = 440.50$ g/mol): monoclinic, space group $P2_1/c$ (no. 14), $a = 11.2258(2)$ Å, $b = 9.78991(18)$ Å, $c = 19.3208(3)$ Å, $\beta = 103.8379(19)^\circ$, $V = 2061.71(7)$ Å³, $Z = 4$, $T = 100(2)$ K, $\mu(\text{CuK}\alpha) = 1.730$ mm⁻¹, $D_{\text{calc}} = 1.419$ g/cm³, 14079 reflections measured ($8.112^\circ \leq 2\theta \leq 139.968^\circ$), 3904 unique ($R_{\text{int}} = 0.0260$, $R_{\text{sigma}} = 0.0217$) which were used in all calculations. The final R_1 was 0.0411 ($I > 2\sigma(I)$) and wR_2 was 0.1052 (all data).


CCDC 1503101



Crystal structure determination of *anti*-10a'

Crystal Data for $C_{23}H_{23}NO_3$ ($M = 361.42$ g/mol): monoclinic, space group Cc (no. 9), $a = 19.3213(7)$ Å, $b = 13.2486(4)$ Å, $c = 7.3482(2)$ Å, $\beta = 109.212(3)^\circ$, $V = 1776.24(10)$ Å³, $Z = 4$, $T = 100(2)$ K, $\mu(\text{CuK}\alpha) = 0.713$ mm⁻¹, $D_{\text{calc}} = 1.352$ g/cm³, 12942 reflections measured ($8.248^\circ \leq 2\theta \leq 144.844^\circ$), 2996 unique ($R_{\text{int}} = 0.0456$, $R_{\text{sigma}} = 0.0265$) which were used in all calculations. The final R_1 was 0.0353 ($I > 2\sigma(I)$) and wR_2 was 0.0945 (all data).


CCDC 1503098



Crystal structure determination of *anti*-10c

Crystal Data for $C_{22}H_{20}FNO_3$ ($M=365.39$ g/mol): monoclinic, space group $C2/c$ (no. 15), $a = 22.2110(8)$ Å, $b = 13.4818(4)$ Å, $c = 15.1581(6)$ Å, $\beta = 131.494(2)^\circ$, $V = 3399.8(2)$ Å³, $Z = 8$, $T = 100(2)$ K, $\mu(\text{MoK}\alpha) = 0.102$ mm⁻¹, $D_{\text{calc}} = 1.428$ g/cm³, 15635 reflections measured ($6.044^\circ \leq 2\theta \leq 54.996^\circ$), 3905 unique ($R_{\text{int}} = 0.0254$, $R_{\text{sigma}} = 0.0218$) which were used in all calculations. The final R_1 was 0.0443 ($I > 2\sigma(I)$) and wR_2 was 0.1214 (all data).


CCDC 1503094



Crystal structure determination of *anti*-10f

Crystal Data for $C_{23}H_{24}N_2O_5S$ ($M=440.50$ g/mol): monoclinic, space group $P2_1/c$ (no. 14), $a = 14.5219(6)$ Å, $b = 14.0079(4)$ Å, $c = 10.9021(4)$ Å, $\beta = 109.892(4)^\circ$, $V = 2085.39(13)$ Å³, $Z = 4$, $T = 200(2)$ K, $\mu(\text{MoK}\alpha) = 0.194$ mm⁻¹, $D_{\text{calc}} = 1.403$ g/cm³, 26903 reflections measured ($5.966^\circ \leq 2\theta \leq 54.998^\circ$), 4782 unique ($R_{\text{int}} = 0.0229$, $R_{\text{sigma}} = 0.0173$) which were used in all calculations. The final R_1 was 0.0370 ($I > 2\sigma(I)$) and wR_2 was 0.0989 (all data).


CCDC 1503099



Crystal structure determination of *anti*-10d

Crystal Data for $C_{23}H_{23}NO_3$ ($M=361.42$ g/mol): orthorhombic, space group $P2_12_12_1$ (no. 19), $a = 7.2945(3)$ Å, $b = 14.2074(6)$ Å, $c = 17.4589(7)$ Å, $V = 1809.36(13)$ Å³, $Z = 4$, $T = 100(2)$ K, $\mu(\text{MoK}\alpha) = 0.088$ mm⁻¹, $D_{\text{calc}} = 1.327$ g/cm³, 14046 reflections measured ($5.478^\circ \leq 2\theta \leq 54.994^\circ$), 4173 unique ($R_{\text{int}} = 0.0350$, $R_{\text{sigma}} = 0.0441$) which were used in all calculations. The final R_1 was 0.0399 ($I > 2\sigma(I)$) and wR_2 was 0.0869 (all data).


CCDC 1503095



Crystal structure determination of *anti*-10h

Crystal Data for $C_{20}H_{19}NO_3$ ($M=321.36$ g/mol): orthorhombic, space group $Pbca$ (no. 61), $a = 14.9929(3)$ Å, $b = 12.2708(3)$ Å, $c = 16.6823(4)$ Å, $V = 3069.13(12)$ Å³, $Z = 8$, $T = 100(2)$ K, $\mu(\text{CuK}\alpha) = 0.755$ mm⁻¹, $D_{\text{calc}} = 1.391$ g/cm³, 21935 reflections measured ($10.606^\circ \leq 2\theta \leq 144.948^\circ$), 2942 unique ($R_{\text{int}} = 0.0610$, $R_{\text{sigma}} = 0.0353$) which were used in all calculations. The final R_1 was 0.0507 ($I > 2\sigma(I)$) and wR_2 was 0.1481 (all data).


CCDC 1470389



Crystal structure determination of *anti*-10b

Crystal Data for $C_{23}H_{23}NO_3$ ($M = 361.42$ g/mol): monoclinic, space group $P2_1/n$ (no. 14), $a = 9.2717(2)$ Å, $b = 11.18826(19)$ Å, $c = 17.5072(4)$ Å, $\beta = 105.013(2)^\circ$, $V = 1754.11(7)$ Å³, $Z = 4$, $T = 100(2)$ K, $\mu(\text{CuK}\alpha) = 0.722$ mm⁻¹, $D_{\text{calc}} = 1.369$ g/cm³, 9756 reflections measured ($9.478^\circ \leq 2\theta \leq 144.978^\circ$), 3397 unique ($R_{\text{int}} = 0.0237$, $R_{\text{sigma}} = 0.0205$) which were used in all calculations. The final R_1 was 0.0516 ($I > 2\sigma(I)$) and wR_2 was 0.1243 (all data).

CCDC 1470399



Crystal structure determination of *anti*-10j

Crystal Data for $C_{20}H_{18}N_2O_5$ ($M = 366.36$ g/mol): monoclinic, space group $P2_1/c$ (no. 14), $a = 8.8454(3)$ Å, $b = 14.1900(4)$ Å, $c = 13.5995(4)$ Å, $\beta = 104.646(3)^\circ$, $V = 1651.50(9)$ Å³, $Z = 4$, $T = 100(2)$ K, $\mu(\text{MoK}\alpha) = 0.107$ mm⁻¹, $D_{\text{calc}} = 1.473$ g/cm³, 14296 reflections measured ($5.558^\circ \leq 2\theta \leq 54.998^\circ$), 3807 unique ($R_{\text{int}} = 0.0259$, $R_{\text{sigma}} = 0.0249$) which were used in all calculations. The final R_1 was 0.0398 ($I > 2\sigma(I)$) and wR_2 was 0.1001 (all data).


CCDC 1461790


6. References:

1. Golubev, P.; Bakulina, O.; Dar'in, D.; Krasavin, M. *Eur. J. Org. Chem.*, **2016**, 3969.
2. Ji, C.; Ma, L.; Yin, M.; Yang, W.; Pan, K. *Chem. Asian J.*, **2016**, *11*, 2316.
3. Szaloki, G.; Sanguinet, L. *J. Org. Chem.*, **2015**, *80*, 3949.
4. Balmond, E. I.; Tautegg, B. K.; Faulkner, A. L.; Or, V. W.; Hodur, B. M.; Shaw, J. T.; Louie, A. Y. *J. Org. Chem.*, **2016**, *81*, 8744.
5. Schultz-Senft, M.; Gates, P. J.; Soennichsen, F. J.; Stanbitz, A. *Dyes Pigm.*, **2017**, *136*, 292.
6. Prostoba, Y.; Coelho, P. J.; Pina, J.; Seixas de Melo, J. *J. Photochem. Photobiol.*, **2010**, *216*, 59.
7. Gore, S.; Baskaran, S.; Koenig, B. *Org. Lett.*, **2012**, *14*, 4568.
8. Li, H.; Luan, Z.-J.; Zheng, G.-W.; Xu, J.-H. *Adv. Synth. Catal.*, **2015**, *357*, 1692.
9. Deniz, E.; Battal, M.; Cusido, J.; Sortino, S.; Raymo, F. M. *Phys. Chem. Chem. Phys.*, **2012**, *14*, 10300.
10. Lin, A.; Yang, J.; Hashim, M. *Org. Lett.*, **2013**, *15*, 1950.
11. Kwan, E.E.; Shaw, G.H. *Eur. J. Org. Chem.* **2008**, 2671–2688.
12. Bifulco, G.; Dambruoso, P.; Gomez-Paloma, L.; Riccio, R. *Chem. Rev.*, **2007**, *107*, 3744.
13. Palatinus, L. & Chapuis, G. (2007). *J. Appl. Cryst.*, *40*, 786-790; Palatinus, L. & van der Lee, A. (2008). *J. Appl. Cryst.* *41*, 975-984; Palatinus, L., Prathapa, S. J. & van Smaalen, S. (2012). *J. Appl. Cryst.* *45*, 575-580.
14. Sheldrick, G.M. (2008). *Acta Cryst. A* *64*, 112-122.
15. Sheldrick, G.M. (2015). *Acta Cryst. C* *71*, 3-8.
16. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J., Howard, J.A.K. & Puschmann, H. (2009), *J. Appl. Cryst.* *42*, 339-341.



17. Spek, A. L. PLATON, A Multipurpose Crystallographic Tool; Utrecht University:
Utrecht, The Netherlands, 2005.

7. Copies of ^1H and ^{13}C NMR spectra of compounds 9 and 10









9c







9m

























anti-10a







anti-10a








































































anti-10m



anti-10m

